![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Lymphoma, Large-cell - 75 Studies Found
Not yet recruiting |
: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma :
|
Completed |
: Large Cell Lymphoma Pilot Study III :
: 2005-09-12 :
|
Recruiting |
: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" : Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma : 2014-04-17 : Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion |
Completed |
: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma :
: 2013-09-23 :
|
Active, not recruiting |
: Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) :
: 2012-08-02 :
|
Completed |
: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma :
: 2008-01-21 : Biological: XmAb2513 Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, |
Active, not recruiting |
: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma :
|
Suspended |
: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma :
|
Recruiting |
: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma :
|